Conformis Stock Forecast, Price & News

+0.06 (+4.03 %)
(As of 08/2/2021 11:40 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume94,660 shs
Average Volume4.20 million shs
Market Capitalization$282.84 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CFMS News and Ratings via Email

Sign-up to receive the latest news and ratings for Conformis and its competitors with MarketBeat's FREE daily newsletter.

Conformis logo

About Conformis

Conformis, Inc., a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers personalized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a personalized bicompartmental knee replacement system; iUni, a personalized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee; and iTotal Identity, a knee system. It also provides Conformis Hip System and Cordera hip replacement, which are hip replacement products; and iJigs, a personalized single-use patient-specific instrumentation. The company markets and sells its products to orthopedic surgeons, hospitals, and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Spain, Portugal, the Netherlands, Belgium, the Dutch Antilles, Suriname, Australia, Argentina, the United Arab Emirates, the Sultanate of Oman, Italy, San Marino, Poland, and other markets. Conformis, Inc. was incorporated in 2004 and is headquartered in Billerica, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.13 out of 5 stars

Medical Sector

427th out of 2,221 stocks

Surgical Appliances & Supplies Industry

9th out of 41 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Conformis (NASDAQ:CFMS) Frequently Asked Questions

Is Conformis a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Conformis in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Conformis stock.
View analyst ratings for Conformis
or view top-rated stocks.

What stocks does MarketBeat like better than Conformis?

Wall Street analysts have given Conformis a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Conformis wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Conformis?

Conformis saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 4,100,000 shares, an increase of 66.7% from the June 15th total of 2,460,000 shares. Based on an average daily trading volume, of 2,410,000 shares, the days-to-cover ratio is currently 1.7 days. Currently, 5.6% of the shares of the company are short sold.
View Conformis' Short Interest

When is Conformis' next earnings date?

Conformis is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Conformis

How can I listen to Conformis' earnings call?

Conformis will be holding an earnings conference call on Wednesday, August 4th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Conformis' earnings last quarter?

Conformis, Inc. (NASDAQ:CFMS) announced its quarterly earnings data on Wednesday, May, 5th. The medical instruments supplier reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by $0.01. The medical instruments supplier earned $13.84 million during the quarter, compared to the consensus estimate of $13.88 million. Conformis had a negative trailing twelve-month return on equity of 83.99% and a negative net margin of 40.00%.
View Conformis' earnings history

How has Conformis' stock price been impacted by COVID-19?

Conformis' stock was trading at $0.66 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CFMS stock has increased by 136.4% and is now trading at $1.56.
View which stocks have been most impacted by COVID-19

What guidance has Conformis issued on next quarter's earnings?

Conformis updated its second quarter 2021 earnings guidance on Wednesday, May, 26th. The company provided earnings per share guidance of - for the period. The company issued revenue guidance of $14 million-$14.50 million, compared to the consensus revenue estimate of $15.12 million.

What price target have analysts set for CFMS?

2 Wall Street analysts have issued twelve-month price targets for Conformis' stock. Their forecasts range from $2.00 to $3.00. On average, they anticipate Conformis' share price to reach $2.50 in the next year. This suggests a possible upside of 60.3% from the stock's current price.
View analysts' price targets for Conformis
or view top-rated stocks among Wall Street analysts.

Who are Conformis' key executives?

Conformis' management team includes the following people:
  • Mr. Mark A. Augusti, CEO, Pres & Director (Age 55, Pay $989.4k)
  • Mr. Robert S Howe, CFO & Treasurer (Age 51, Pay $552.29k) (LinkedIn Profile)
  • Mr. J. Brent Alldredge J.D., Chief Legal Officer & Corp. Sec. (Age 46, Pay $470.5k) (LinkedIn Profile)
  • Mr. Gary Maingot, Sr. VP of Operations
  • Mr. John Slamin, Chief Technology Officer (Age 67)
  • Mr. Farzin Khaghani, VP of U.S. Marketing
  • Ms. Allison Baker, Director of HR
  • Mr. Emmanuel O. Nyakako, Sr. VP of Quality & Regulatory Affairs
  • Eric Rickenbach, Sr. VP of US Sales
  • Mr. Terrance Wong, Sr. VP of HIP & Private Label Engineering

What is Mark Augusti's approval rating as Conformis' CEO?

15 employees have rated Conformis CEO Mark Augusti on Mark Augusti has an approval rating of 55% among Conformis' employees. This puts Mark Augusti in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Conformis' key competitors?

What other stocks do shareholders of Conformis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Conformis investors own include Advanced Micro Devices (AMD), Martin Midstream Partners (MMLP), Micron Technology (MU), NVIDIA (NVDA), Trevena (TRVN), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and AT&T (T).

When did Conformis IPO?

(CFMS) raised $135 million in an initial public offering on Wednesday, July 1st 2015. The company issued 9,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Deutsche Bank Securities acted as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.

What is Conformis' stock symbol?

Conformis trades on the NASDAQ under the ticker symbol "CFMS."

Who are Conformis' major shareholders?

Conformis' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Fort Pitt Capital Group LLC (0.01%). Company insiders that own Conformis stock include Erin Henry, J Brent Alldredge, Kenneth P Fallon III, Mark A Augusti, Mark A Augusti, Paul S Weiner and Robert S Howe.
View institutional ownership trends for Conformis

Which major investors are buying Conformis stock?

CFMS stock was purchased by a variety of institutional investors in the last quarter, including Fort Pitt Capital Group LLC.
View insider buying and selling activity for Conformis
or or view top insider-buying stocks.

How do I buy shares of Conformis?

Shares of CFMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Conformis' stock price today?

One share of CFMS stock can currently be purchased for approximately $1.56.

How much money does Conformis make?

Conformis has a market capitalization of $284.66 million and generates $68.76 million in revenue each year. The medical instruments supplier earns $-24,290,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis.

How many employees does Conformis have?

Conformis employs 259 workers across the globe.

What is Conformis' official website?

The official website for Conformis is

Where are Conformis' headquarters?

Conformis is headquartered at 600 TECHNOLOGY PARK DRIVE, BILLERICA MA, 01821.

How can I contact Conformis?

Conformis' mailing address is 600 TECHNOLOGY PARK DRIVE, BILLERICA MA, 01821. The medical instruments supplier can be reached via phone at 781-345-9001 or via email at [email protected]

This page was last updated on 8/2/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.